AIM – The risks for European public policy making and public health after 4th round of TTIP negotiation
A press release, published by European associations and including AIM partners such as Health Action International, alerts on the consequences that the Transatlantic Trade and Investment Partnership (TTIP) could have on medicine patents, pricing and on national public health policies.
TTIP negotiators work on regulatory coherence and increasing regulatory compatibility to enable enterprises to conduct activities and invest on both sides of the Atlantic.
According to the signatories of this new position including AIM partners, the negotiations give the industry a chance to try to integrate their wishes, among them, expanding the length of medicines patent monopolies, influencing Member States’ regulations to contain costs of medicines and questioning the recent moves by the European Medicines Agency (EMA) towards transparency on clinical trials data.
The proposals about the introduction of an ‘investor-to state-dispute mechanism’ are of particular concern as they give investors the right to sue governments over public decisions deemed harmful to their investments. AIM and its European partners are mobilised and follow the issue closely to provide the EU Commission with position papers to be sure that public health issues will be taken into account.
Originally posted on 11 April 2014